Q2 Earnings Estimate for ARWR Issued By HC Wainwright

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - HC Wainwright issued their Q2 2025 earnings estimates for shares of Arrowhead Pharmaceuticals in a research note issued on Wednesday, February 12th. HC Wainwright analyst P. Trucchio anticipates that the biotechnology company will post earnings of $2.66 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $80.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals' FY2025 earnings at $1.53 EPS, FY2026 earnings at ($4.21) EPS, FY2027 earnings at ($3.27) EPS, FY2028 earnings at ($3.20) EPS and FY2029 earnings at ($1.29) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97).

A number of other analysts also recently issued reports on ARWR. StockNews.com raised shares of Arrowhead Pharmaceuticals to a "sell" rating in a report on Friday, December 20th. Piper Sandler cut their price objective on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, November 27th. Citigroup decreased their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating on the stock in a research note on Wednesday, November 27th. Royal Bank of Canada reissued an "outperform" rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Sanford C. Bernstein decreased their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating on the stock in a report on Friday, November 29th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $41.44.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock traded down $0.12 during mid-day trading on Monday, hitting $20.96. 1,306,397 shares of the company traded hands, compared to its average volume of 2,172,943. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. Arrowhead Pharmaceuticals has a one year low of $17.05 and a one year high of $36.72. The stock has a market cap of $2.64 billion, a price-to-earnings ratio of -4.05 and a beta of 0.95. The stock has a fifty day moving average price of $19.83 and a 200-day moving average price of $20.96.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new position in Arrowhead Pharmaceuticals in the 4th quarter worth about $49,000. Neo Ivy Capital Management purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $318,000. Two Sigma Advisers LP increased its position in shares of Arrowhead Pharmaceuticals by 330.7% during the fourth quarter. Two Sigma Advisers LP now owns 430,700 shares of the biotechnology company's stock valued at $8,097,000 after acquiring an additional 330,700 shares in the last quarter. Two Sigma Investments LP raised its holdings in Arrowhead Pharmaceuticals by 281.3% in the 4th quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company's stock worth $14,934,000 after acquiring an additional 586,062 shares during the last quarter. Finally, Tema Etfs LLC bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $1,156,000. Hedge funds and other institutional investors own 62.61% of the company's stock.

Insider Buying and Selling

In other news, Director William D. Waddill sold 3,748 shares of the company's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $21.90, for a total value of $82,081.20. Following the sale, the director now directly owns 44,125 shares of the company's stock, valued at $966,337.50. This represents a 7.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Adeoye Y. Olukotun sold 2,850 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. Following the transaction, the director now directly owns 36,740 shares of the company's stock, valued at approximately $734,800. This trade represents a 7.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 147,432 shares of company stock valued at $2,957,986 over the last quarter. 4.30% of the stock is owned by company insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.